Volume 377, Issue 9783, Pages (June 2011)

Slides:

Advertisements

Similar presentations

Volume 14, Issue 12, Pages (November 2013)

Advertisements

Volume 14, Issue 4, Pages (April 2013)

Volume 16, Issue 2, Pages (February 2015)

Volume 18, Issue 6, Pages (June 2017)

Volume 11, Issue 8, Pages (August 2010)

Volume 376, Issue 9747, Pages (October 2010)

Volume 18, Issue 7, Pages (July 2017)

Volume 11, Issue 4, Pages (April 2012)

Volume 16, Issue 9, Pages (September 2015)

Volume 15, Issue 6, Pages (May 2014)

Volume 378, Issue 9809, Pages (December 2011)

Volume 14, Issue 4, Pages (April 2013)

Volume 377, Issue 9779, Pages (May 2011)

Volume 373, Issue 9666, Pages (March 2009)

Evaluation of early administration of simvastatin in the prevention and treatment of delirium in critically ill patients undergoing mechanical ventilation.

Volume 371, Issue 9611, Pages (February 2008)

Volume 15, Issue 4, Pages (April 2014)

Characteristics and survival of patients with Ebola virus infection, malaria, or both in Sierra Leone: a retrospective cohort study Matthew Waxman, MD,

Volume 15, Issue 4, Pages (April 2014)

Volume 376, Issue 9757, Pages (December 2010)

Volume 14, Issue 12, Pages (December 2015)

Volume 385, Issue 9966, Pages (January 2015)

Volume 15, Issue 4, Pages (April 2014)

Volume 373, Issue 9663, Pages (February 2009)

Volume 14, Issue 7, Pages (June 2013)

Volume 15, Issue 4, Pages (April 2014)

Volume 17, Issue 9, Pages (September 2016)

Volume 14, Issue 8, Pages (July 2013)

Volume 18, Issue 7, Pages (July 2017)

Volume 14, Issue 8, Pages (July 2013)

Volume 12, Issue 7, Pages (July 2011)

Volume 15, Issue 6, Pages (May 2014)

Volume 18, Issue 3, Pages (March 2017)

Volume 379, Issue 9812, Pages (January 2012)

Volume 15, Issue 1, Pages (January 2014)

Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label,

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild- type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised.

Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung.

Volume 14, Issue 11, Pages (October 2013)

Volume 373, Issue 9666, Pages (March 2009)

Volume 10, Issue 9, Pages (September 2009)

Volume 18, Issue 3, Pages (March 2017)

Volume 385, Issue 9962, Pages (January 2015)

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled,

Volume 19, Issue 4, Pages (April 2018)

Volume 15, Issue 8, Pages (July 2014)

Volume 371, Issue 9625, Pages (May 2008)

Volume 373, Issue 9676, Pages (May 2009)

Volume 388, Issue 10055, Pages (October 2016)

Volume 15, Issue 6, Pages (May 2014)

Volume 381, Issue 9880, Pages (May 2013)

Volume 392, Issue 10162, Pages (December 2018)

Volume 14, Issue 6, Pages (May 2013)

Volume 13, Issue 11, Pages (November 2012)

Volume 5, Issue 4, Pages (April 2018)

Volume 375, Issue 9726, Pages (May 2010)

Volume 16, Issue 8, Pages (August 2015)

Volume 378, Issue 9809, Pages (December 2011)

Volume 14, Issue 8, Pages (July 2013)

Volume 375, Issue 9714, Pages (February 2010)

Volume 15, Issue 6, Pages (May 2014)

Volume 15, Issue 1, Pages (January 2014)

Volume 11, Issue 1, Pages (January 2010)

Volume 376, Issue 9757, Pages (December 2010)

Volume 375, Issue 9715, Pages (February 2010)

Volume 376, Issue 9747, Pages (October 2010)

Volume 13, Issue 7, Pages (July 2014)

Volume 14, Issue 7, Pages (June 2013)

Volume 392, Issue 10162, Pages (December 2018)

Volume 371, Issue 9611, Pages (February 2008)

Presentation transcript:

Volume 377, Issue 9783, Pages 2103-2114 (June 2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Prof Timothy S Maughan, FRCR, Richard A Adams, FRCP, Christopher G Smith, BSc, Angela M Meade, DPhil, Prof Matthew T Seymour, FRCP, Richard H Wilson, MD, Shelley Idziaszczyk, MPhil, Rebecca Harris, MSc, David Fisher, MSc, Sarah L Kenny, MSc, Edward Kay, BA, Jenna K Mitchell, BHSc, Ayman Madi, MRCP, Prof Bharat Jasani, FRCPath, Michelle D James, BSc, John Bridgewater, MD, M John Kennedy, MD, Bart Claes, MSc, Diether Lambrechts, PhD, Prof Richard Kaplan, MD, Prof Jeremy P Cheadle, PhD The Lancet Volume 377, Issue 9783, Pages 2103-2114 (June 2011) DOI: 10.1016/S0140-6736(11)60613-2 Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile EGFR=epidermal growth factor receptor. The Lancet 2011 377, 2103-2114DOI: (10.1016/S0140-6736(11)60613-2) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 2 Kaplan-Meier overall survival curves for patients with (A) KRAS wild-type, (B) KRAS mutant, (C) BRAF mutant and KRAS wild-type, and (D) KRAS, NRAS, and BRAF all wild-type tumours HR=hazard ratio. The Lancet 2011 377, 2103-2114DOI: (10.1016/S0140-6736(11)60613-2) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 3 Tumour mutational status as a prognostic factor for overall survival HR=hazard ratio. The Lancet 2011 377, 2103-2114DOI: (10.1016/S0140-6736(11)60613-2) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 4 Exploratory predictive factor analyses HR=hazard ratio. The Lancet 2011 377, 2103-2114DOI: (10.1016/S0140-6736(11)60613-2) Copyright © 2011 Elsevier Ltd Terms and Conditions